An unexpected version of horror autotoxicus: Anaphylactic shock to a self-peptide

Nature Immunology

Volumn 2, Issue 3, 2001, Pages 216-222

  Pedotti, Rosetta ^a,c   Mitchell, Dennis ^a   Wedemeyer, Jochen ^b   Karpuj, Marcela ^a   Chabas, Dorothée ^a   Hattab, Eyas M ^b   Tsai, Mindy ^b   Galli, Stephen J ^b   Steinman, Lawrence ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; AUTOANTIBODY; AUTOANTIGEN; FREUND ADJUVANT; HISTAMINE; PEPTIDE; PEPTIDE FRAGMENT; PROTEOLIPID PROTEIN; PROTEOLIPID PROTEIN 139 151; PROTEOLIPID PROTEIN 139-151; SEROTONIN;

ALLERGIC ENCEPHALOMYELITIS; ANAPHYLAXIS; ANIMAL; ARTICLE; AUTOIMMUNITY; BIOSYNTHESIS; FEMALE; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; MOUSE; PATHOLOGY; PHYSIOLOGY; THYMUS;

ALLERGENS; ANAPHYLAXIS; ANIMALS; AUTOANTIBODIES; AUTOANTIGENS; AUTOIMMUNITY; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; FREUND'S ADJUVANT; HISTAMINE; IMMUNE TOLERANCE; MICE; MYELIN PROTEOLIPID PROTEIN; PEPTIDE FRAGMENTS; PEPTIDES; SEROTONIN; THYMUS GLAND;

EID: 0035286208     PISSN: 15292908     EISSN: None     Source Type: Journal    
DOI: 10.1038/85266     Document Type: Article

References (55)

1. Vandenbark, A. A. et al. Specificity of T lymphocyte lines for peptides of myelin basic protein. J. Immunol. 135, 229-233 (1985).
2. Brosnan, C. F., Selmaj, K. & Raine, C. S. Hypothesis: a role for tumor necrosis factor in immune-mediated demyelination and its relevance to multiple sclerosis. J. Neuroimmunol. 18, 87-94 (1988).
3. Abbas, A. K., Murphy, K. M. & Sher, A. Functional diversity of helper T lymphocytes. Nature 383, 787-793 (1996).
4. Bochner, B. S. & Lichtenstein, L. M. Anaphylaxis. N. Engl. J. Med. 324, 1785-1790 (1991).
5. Galli, S. J. & Lantz, C. S. in Fundamental Immunology (ed. Paul, W. E.) 1137-1184 (Lippincott-Raven Press, Philadelphia, 1999).
6. Ishizaka, T. & Ishizaka, K. Activation of mast cells for mediator release through IgE receptors. Prog. Allergy 34, 188-235 (1984).
7. Mota, I. & Wong, D. Homologous and heterologous passive cutaneous anaphylactic activity of mouse antisera during the course of immunization. Life Sci. 8, 13-820 (1969).
8. Miyajima, I. et al. Systemic anaphylaxis in the mouse can be mediated largely through IgG1 and FcγRIII. Assessment of the cardiopulmonary changes, mast cell degranulation, and death associated with active or IgE- or IgG1-dependent passive anaphylaxis. J. Clin. Invest. 99, 901-914 (1997).
9. + T cells in the pathogenesis of organspecific autoimmune diseases. Immunol. Today 16, 34-38 (1995).
10. Lafaille, J. J. et al. Myelin basic protein-specific T helper 2 (Th2) cells cause experimental autoimmune encephalomyelitis in immunodeficient hosts rather than protect them from the disease. J. Exp. Med. 186, 307-312 (1997).
11. Linthicum, D. S. Development of acute autoimmune encephalomyelitis in mice: factors regulating the effector phase of the disease. Immunobiology 162, 211-220 (1982).
12. Dietsch, G. N. & Hinrichs, D. J. The role of mast cells in the elicitation of experimental allergic encephalomyelitis. J. Immunol. 142, 1476-1481 (1989).
13. Bebo, B. F. Jr, Lee, C. H., Orr, E. L. & Linthicum, D. S. Mast cell-derived histamine and tumour necrosis factor: differences between SJL/J and BALB/c inbred strains of mice. Immunol. Cell. Biol. 74, 225-230 (1996).
14. Brenner, T., Soffer, D., Shalit, M. & Levi-Schaffer, F. Mast cells in experimental allergic encephalomyelitis: characterization, distribution in the CNS and in vitro activation by myelin basic protein and neuropeptides. J. Neurol. Sci. 122, 210-213 (1994).
15. Toms, R., Weiner, H. L. & Johnson, D. Identification of IgE-positive cells and mast cells in frozen sections of multiple sclerosis brains. J. Neuroimmunol. 30, 169-177 (1990).
16. Olsson, Y. Mast cells in plaques of multiple sclerosis. Acta Neurol. Scand. 50, 611-418 (1974).
17. Kruger, P. G. et al. Mast cells and multiple sclerosis: a light and electron microscopic study of mast cells in multiple sclerosis emphasizing staining procedures. Acta Neurol. Scand. 81, 31-36 (1990).
18. Linthicum, D. S. & Frelinger, J. A Acute autoimmune encephalomyelitis in mice. II. Susceptibility is controlled by the combination of H-2 and histamine sensitization genes. J. Exp. Med. 156, 31-40 (1982).
19. Johnson, D., Seeldrayers, P. A. & Weiner, H. L. The role of mast cells in demyelination. I. Myelin proteins are degraded by mast cell proteases and myelin basic protein and P2 can stimulate mast cell degranulation. Brain Res. 444, 195-198 (1988).
20. Dines, K. C. & Powell, H. C. Mast cell interactions with the nervous system: relationship to mechanisms of disease. J. Neuropathol. Exp. Neurol. 56, 627-640 (1997).
21. Secor, V. H., Secor, W. E., Gutekunst, C. A. & Brown, M. A. Mast cells are essential for early onset and severe disease in a murine model of multiple sclerosis. J. Exp. Med. 191, 813-822 (2000).
22. Linthicum, D. S., Munoz, J. J. & Blaskett, A. Acute experimental autoimmune encephalomyelitis in mice. I. Adjuvant action of Bordetella pertussis is due to vasoactive amine sensitization and increased vascular permeability of the central nervous system. Cell. Immunol. 73, 299-310 (1982).
23. Soloway, P. et al. Regulation of the immune response to peptide antigens: differential induction of immediate-type hypersensitivity and T cell proliferation due to changes in either peptide structure or major histocompatibility complex haplotype. J. Exp. Med. 174, 847-858 (1991).
24. Dombrowicz, D. et al. Absence of FcεRI α chain results in upregulation of FcγRIII-dependent mast cell degranulation and anaphylaxis. Evidence of competition between FcεRI and FcγRIII for limiting amounts of FcR β and γ chains. J. Clin. Invest. 99, 915-925 (1997).
25. Kuchroo, V. K. et al. A single TCR antagonist peptide inhibits experimental allergic encephalomyelitis mediated by a diverse T cell repertoire. J. Immunol. 153, 3326-3336 (1994).
26. Hurtenbach, U., Lier, E., Adorini, L. & Nagy, Z. A. Prevention of autoimmune diabetes in non-obese diabetic mice by treatment with a class II major histocompatibility complex-blocking peptide. J. Exp. Med. 177, 1499-1504 (1993).
27. Tuohy, V. K., Lu, Z., Sobel, R. A., Laursen, R. A. & Lees, M. B. Identification of an encephalitogenic determinant of myelin proteolipid protein for SJL mice. J. Immunol. 142, 1523-1527 (1989).
28. Anderson, A. C. et al. High frequency of autoreactive myelin proteolipid protein-specific T cells in the periphery of naive mice: mechanisms of selection of the self-reactive repertoire. J. Exp. Med. 191, 761-770 (2000).
29. Encinas, J. A., Weiner, H. L. & Kuchroo, V. K. Inheritance of susceptibility to experimental autoimmune encephalomyelitis. J. Neurosci. Res. 45, 655-669 (1996).
30. Steinman, L. et al. Murine model for pertussis vaccine encephalopathy: linkage to H-2. Nature. 299, 738-740 (1982).
31. Pribyl, T. M. et al. The human myelin basic protein gene is included within a 179-kilobase transcription unit expression in ihe immune and central nervous systems. Proc. Natl. Acad. Sci. USA 90, 10695-10699 (1993).
32. Zelenika, D., Grima, B. & Pessac, B. A new family of transcripts of the myelin basic protein gene: expression in brain and in immune system. J. Neurochem. 60, 1574-1577 (1993).
33. Radu, C. G., Anderton, S. M., Firan, M., Wraith, D. C. & Ward, E. S. Detection of autoreactive T cells in H-2(u) mice using peptide-MHC multimers. Int. Immunol. 12, 1553-1560 (2000).
34. Liu, G. Y. et al. Low avidity recognition of self-antigen by T cells permits escape from central tolerance. Immunity. 3, 407-415 (1995).
35. Zamvil, S. et al. T-cell clones specific for myelin basic protein induce chronic relapsing paralysis and demyelination. Nature 317, 355-358 (1985).
36. Zamvil, S. S. et al. T-cell epitope of the autoantigen myelin basic protein that induces encephalomyelitis. Nature 324, 258-260 (1986).
37. Jensen, M. A., Dayal, A. & Arnason, B. G. Cytokine secretion by δγ and αβT cells in monophasic experimental autoimmune encephalomyelitis. J. Autoimmun. 12, 73-80 (1999).
38. Begolka, W. S., Vanderlugt, C. L., Rahbe, S. M. & Miller, S. D. Differential expression of inflammatory cytokines parallels progression of central nervous system pathology in two clinically distinct models of multiple sclerosis. J. Immunol. 161, 4437-4446 (1998).
39. Faquim-Mauro, E. L., Coffman, R. L., Abrahamsohn, I. A. & Macedo, M. S. Cutting edge: mouse IgG1 antibodies comprise two functionally distinct types that are differentially regulated by IL-4 and IL-12. J. Immunol. 163, 3572-3576 (1999).
40. Kim, R. Anaphylaxis to protamine masquerading as an insulin allergy. Dev. Med. J. 65, 17-23 (1993).
41. Schernthaner, G. Immunogenicity and allergenic potential of animal and human insulins. Diabetes Care 16, 155-165 (1993).
42. Bove, J. R. & McIntosh, S. Anaphylactic reaction to purified anti-hemophilic factor concentrate. Transfusion 28, 603 (1988).
43. Shopnick, R. I. et al. Anaphylaxis after treatment with recombinant factor VIII. Transfusion 36, 358-361 (1996).
44. Davis, H. M. et al. Lack of immune response to mouse IgG in hemophilia A patients treated chronically with Monoclate, a monoclonal antibody affinity purified factor VIII preparation. Thromb. Haemost. 63, 386-391 (1990).
45. Oro, A. S., Guarino, T. J., Driver, R., Steinman, L. & Umetsu, D. T. Regulation of disease susceptibility: decreased prevalence of IgE- mediated allergic disease in patients with multiple sclerosis. J. Allergy Clin. Immunol. 97, 1401-1408 (1996).
46. Kappos, L. et al. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. Nature Med. 6, 1176-1182 (2000).
47. Genain, C. P. et al. Late complications of immune deviation therapy in a nonhuman primate. Science 274, 2054-2057 (1996).
48. Klein, L., Klugmann, M., Nave, K. A. & Kyewski, B. Shaping of the autoreactive T-cell repertoire by a splice variant of self protein expressed in thymic epithelial cells. Nature Med. 6, 56-61 (2000).
49. Steinman, L. Multiple approaches to multiple sclerosis. Nature Med. 6, 15-16 (2000).
50. Schwartz, M. & Cohen, I. R. Autoimmunity can benefit self-maintenance. Immunol. Today 21, 265-268 (2000).
51. Ruiz, P. J. et al. Suppressive immunization with DNA encoding a self-peptide prevents autoimmune disease: modulation of T cell costimulation. J. Immunol. 162, 3336-3341 (1999).
52. Waisman, A. et al. Suppressive vaccination with DNA encoding a variable region gene of the T-cell receptor prevents autoimmune encephalomyelitis and activates Th2 immunity. Nature Med. 2, 899-905 (1996).
53. Spergel, J. M. et al. Epicutaneous sensitization with protein antigen induces localized allergic dermatitis and hyperresponsiveness to methacholine after single exposure to aerosolized antigen in mice. J. Clin. Invest. 101, 1614-1622 (1998).
54. Wershil, B. K., Murakami, T. & Galli, S. J. Mast cell-dependent amplification of an immunologically non-specific inflammatory response. Mast cells are required for the full expression of cutaneous acute inflammation induced by phorbol 12-myristate 13-acetate. J. Immunol. 140, 2356-2360 (1988).
55. Williams, C. M. & Galli, S. J. Mast cells can amplify airway reactivity and features of chronic inflammation in an asthma model in mice. J. Exp. Med. 192, 455-462 (2000).